Advanced

Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay

Fernö, Mårten LU ; Bendahl, Pär-Ola LU ; Borg, Åke LU ; Brundell, J; Hirschberg, L; Olsson, Håkan LU and Killander, Dick LU (1996) In European Journal of Cancer 32a(5). p.793-801
Abstract
Urokinase plasminogen activator (uPA) is involved in the activation of different proteases which participate in the degradation of extracellular matrix, thereby enhancing the invasive capacity of tumour cells. uPA has been shown to be of prognostic importance in breast cancer. We have analysed uPA with a new luminometric immunoassay (LIA), applicable in cytosol samples routinely used for oestrogen-receptor (ER) and progesterone-receptor (PgR) analyses. At a cut-off value of 0.62 ng uPA/mg protein, 33% (230/688) samples were classified as representing high uPA tumours. High uPA content was found to be associated with shorter recurrence-free survival (median observation time: 42 months), ER and PgR negativity, increased p53 expression, DNA... (More)
Urokinase plasminogen activator (uPA) is involved in the activation of different proteases which participate in the degradation of extracellular matrix, thereby enhancing the invasive capacity of tumour cells. uPA has been shown to be of prognostic importance in breast cancer. We have analysed uPA with a new luminometric immunoassay (LIA), applicable in cytosol samples routinely used for oestrogen-receptor (ER) and progesterone-receptor (PgR) analyses. At a cut-off value of 0.62 ng uPA/mg protein, 33% (230/688) samples were classified as representing high uPA tumours. High uPA content was found to be associated with shorter recurrence-free survival (median observation time: 42 months), ER and PgR negativity, increased p53 expression, DNA non-diploidy and a high S-phase fraction (SPF), but not with lymph node involvement or tumour size (< or = 20 mm versus > 20 mm). In the subgroup of patients not treated with systemic adjuvant therapy, multivariate analysis showed uPA to be an independent prognostic factor together with lymph node status and SPF. If these results can be reproduced, uPA may be a factor suitable for inclusion in a prognostic index. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Cancer
volume
32a
issue
5
pages
793 - 801
publisher
Elsevier
external identifiers
  • pmid:9081356
  • scopus:0029950191
ISSN
1879-0852
DOI
10.1016/0959-8049(95)00652-4
language
English
LU publication?
yes
id
70099f50-609c-4ef7-a6a9-9b161e2ed595 (old id 1111138)
date added to LUP
2008-07-23 09:25:15
date last changed
2017-01-01 04:35:23
@article{70099f50-609c-4ef7-a6a9-9b161e2ed595,
  abstract     = {Urokinase plasminogen activator (uPA) is involved in the activation of different proteases which participate in the degradation of extracellular matrix, thereby enhancing the invasive capacity of tumour cells. uPA has been shown to be of prognostic importance in breast cancer. We have analysed uPA with a new luminometric immunoassay (LIA), applicable in cytosol samples routinely used for oestrogen-receptor (ER) and progesterone-receptor (PgR) analyses. At a cut-off value of 0.62 ng uPA/mg protein, 33% (230/688) samples were classified as representing high uPA tumours. High uPA content was found to be associated with shorter recurrence-free survival (median observation time: 42 months), ER and PgR negativity, increased p53 expression, DNA non-diploidy and a high S-phase fraction (SPF), but not with lymph node involvement or tumour size (&lt; or = 20 mm versus &gt; 20 mm). In the subgroup of patients not treated with systemic adjuvant therapy, multivariate analysis showed uPA to be an independent prognostic factor together with lymph node status and SPF. If these results can be reproduced, uPA may be a factor suitable for inclusion in a prognostic index.},
  author       = {Fernö, Mårten and Bendahl, Pär-Ola and Borg, Åke and Brundell, J and Hirschberg, L and Olsson, Håkan and Killander, Dick},
  issn         = {1879-0852},
  language     = {eng},
  number       = {5},
  pages        = {793--801},
  publisher    = {Elsevier},
  series       = {European Journal of Cancer},
  title        = {Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay},
  url          = {http://dx.doi.org/10.1016/0959-8049(95)00652-4},
  volume       = {32a},
  year         = {1996},
}